Lucid diagnostics secures national VA contract as EsoGuard revenue climbs
Lucid Diagnostics (NASDAQ:LUCD), a commercial-stage medical diagnostics company focused on the early detection of esophageal precancer, today reported financial and operational results for the fourth quarter and full year ended December 31, 2025.


_1368625_640x360_2493808195573-640x360.webp&w=1200&q=75)


-640x360.jpg&w=1200&q=75)
-640x360.jpg&w=1200&q=75)













